ALK and non-small cell lung carcinoma: Currently, the nivolumab plus ipilimumab combination demonstrated superior survival compared with chemotherapy in the CheckMate-227 trial, leading to its approval for metastatic NSCLC (squamous or non-squamous) without EGFR or ALK genomic alterations with PD-L1 expression  ≥ 1% [14, 15].